Adjuvant (RTOG 3506 STEEL)

A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features.

The primary goal of this study is to determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

Principal Investigator

Christopher Jones, MD

Co-Investigator(s)

Sivakumar Reddy, M.D., David S Yee, M.D., MPH, Seth A Rosenthal, Radiation Oncologist